High granularity immune phenotyping in ageing – towards molecular markers of declined immunity, chronic inflammation and neurodegenerative disease

Revealing the role of inflammation and blood-brain barrier integrity in Alzheimer’s disease pathology

We will correlate clinical phenotype, MRI and PET CNS imaging, immune subset transcriptomics and systemic inflammation. We will identify highly characterized, amyloid positive (using amyloid PET) Alzheimer’s subjects and controls (amyloid negative) and conduct detailed clinical, neurological and neuropsychological evaluation.

1) an established link between age-related declined immunity, BBB dysfunction and the progression of AD which identifies new targets for early intervention, 2) early diagnosis of AD trajectory in individuals exhibiting amyloid deposition in the brain and/or MCI, and 3) different trajectory patterns of individuals diagnosed with AD, which then allows personalized treatment and better treatment efficacy.